Results 191 to 200 of about 19,412 (203)

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib

Radiotherapy and Oncology, 2020
Jinming Yu, Hui Zhu, Hongbo Guo
exaly  

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Annals of Oncology, 2019
Adam Schoenfeld, Matthew Hellmann, K C Arbour   +2 more
exaly  

High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression

Lung Cancer, 2016
Siraj Ali, Sai-Hong Ou
exaly  

Osimertinib-Induced Cardiomyopathy

JACC: Case Reports, 2020
Shruti Patel, Sherry-Ann Brown, Narjust Florez   +2 more
exaly  

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

Lung Cancer, 2019
Kammei Rai, Katsuyuki Hotta, Kiichiro Ninomiya   +2 more
exaly  

Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor

Bioorganic Chemistry, 2019
Hong-Min Liu, Yi-Chao Zheng, Bin Yu
exaly  

Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA

Annals of Oncology, 2017
Claudio Nicotra, C Jovelet, K Howarth
exaly  

Osimertinib

Reactions Weekly, 2016
openaire   +1 more source

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

Annals of Oncology
Tae Min Kim, Clarissa Baldotto, Javier de Castro   +2 more
exaly  

Osimertinib-Induced Cardiotoxicity

JACC: CardioOncology, 2019
Eric Bernicker, Barry Trachtenberg, Joe Ensor   +2 more
exaly